Parse Biosciences and bit.bio have announced a strategic alliance designed to create one of the most comprehensive datasets ever assembled on transcription factor-driven cell identity. The collaboration seeks to unlock deeper understanding of how genetic instructions influence cell behavior, enabling the development of more accurate human biological models and accelerating progress in drug discovery and therapeutic development.
The initiative will combine cutting-edge technologies from both organizations to generate an extensive map connecting genetic inputs to biological outcomes. By capturing detailed relationships between cell state, cell fate and gene regulation, the project aims to provide researchers with a powerful resource for understanding human biology at unprecedented scale and resolution.
Central to the collaboration is the use of massively parallel causal transcriptomics, an advanced scientific approach that allows researchers to evaluate thousands of genetic variables simultaneously. This methodology enables scientists to identify the specific factors that drive cellular behavior and determine how different genetic programs influence biological functions.
bit.bio will contribute its proprietary opti-oxâ„¢ cell programming technology and its Discovery platform, known as The Cell Foundryâ„¢, which enables precise conversion of induced pluripotent stem cells into targeted human cell types. Parse Biosciences will provide its Evercodeâ„¢ single-cell sequencing technology, which supports highly scalable and detailed analysis of cellular activity across large populations of cells.
Together, these technologies will generate a unique dataset mapping the effects of individual transcription factors and genetic combinations on cell development and function. The resulting information is expected to expand significantly upon existing proprietary datasets and establish a robust framework for future biological research.
The collaboration is intended to support the creation of highly accurate human-relevant models capable of reproducing biological responses observed in living systems. Such models are increasingly important for evaluating drug candidates, studying disease mechanisms and reducing reliance on less predictive experimental systems.
Researchers anticipate that the resulting data will also play an important role in the advancement of artificial intelligence applications in life sciences. By providing detailed causal relationships between genetic changes and cellular outcomes, the dataset can be used to train predictive models that forecast how cells respond to drugs, environmental conditions and disease processes.
Beyond drug discovery, the findings are expected to contribute to improvements in cell manufacturing and regenerative medicine. Understanding how transcription factors govern cell identity could help scientists develop more efficient methods for producing specialized human cells at industrial scale for research and therapeutic applications.
The alliance reflects growing momentum across the biotechnology sector toward integrating advanced cell programming, genomic analysis and artificial intelligence to address complex biological challenges. By combining complementary expertise in cellular engineering and single-cell sequencing, Parse Biosciences and bit.bio aim to create foundational scientific resources that can support innovation across multiple areas of biomedical research.
The project’s outcomes are expected to benefit not only the participating organizations but also the broader scientific community by providing deeper insights into the mechanisms that control human cell behavior. As predictive biology continues to emerge as a transformative field, comprehensive datasets linking genetics to function will become increasingly valuable for advancing precision medicine and next-generation therapeutic development.
